Molecular Templates (MTEM) Stock Price, News & Analysis

Company Overview

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Key Stats

• Today's Range: $0.45 to $0.46
• 50-Day Range: $0.33 to $1.53
• 52-Week Range: $0.30 to $6.25
• Volume: 67,536 shs
• Average Volume: 13.52 million shs
• Market Capitalization: $3.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Molecular Templates Stock Analysis - MarketRank™

Molecular Templates scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Molecular Templates.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Molecular Templates is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Molecular Templates is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Molecular Templates has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.62% of the float of Molecular Templates has been sold short.

Short Interest Ratio / Days to Cover

Molecular Templates has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Molecular Templates has recently increased by 77.17%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Molecular Templates does not currently pay a dividend.

Dividend Growth

Molecular Templates does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.93

Percentage of Shares Shorted

4.62% of the float of Molecular Templates has been sold short.

Short Interest Ratio / Days to Cover

Molecular Templates has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Molecular Templates has recently increased by 77.17%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Molecular Templates has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Molecular Templates insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.60% of the stock of Molecular Templates is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.47% of the stock of Molecular Templates is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MTEM Stock Analysis - Frequently Asked Questions

How have MTEM shares performed this year?

Molecular Templates' stock was trading at $3.73 at the start of the year. Since then, MTEM shares have decreased by 87.7% and is now trading at $0.4578.
View the best growth stocks for 2024 here.

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) issued its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported ($1.23) EPS for the quarter. The biotechnology company earned $0.57 million during the quarter. Molecular Templates had a negative trailing twelve-month return on equity of 260.50% and a negative net margin of 61.35%.

When did Molecular Templates' stock split?

Molecular Templates shares reverse split before market open on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Molecular Templates?

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Templates investors own include NVIDIA (NVDA), Meta Platforms (META), General Electric (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Alibaba Group (BABA) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 11/02/2024
• Next Earnings (Estimated): 11/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MTEM
• CUSIP: 88580720
• CIK: 1183765
• Web: www.mtem.com
• Phone: (512) 869-1555
• Fax: 650-474-2529
• Employees: 62
• Year Founded: 2009

Profitability

• EPS (Most Recent Fiscal Year): ($2.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,120,000.00
• Net Margins: -61.35%
• Pretax Margin: -61.39%
• Return on Equity: -260.50%
• Return on Assets: -46.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.56
• Quick Ratio: 1.56

Sales & Book Value

• Annual Sales: $57.31 million
• Price / Sales: 0.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.78 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 6,580,000
• Free Float: 5,689,000
• Market Cap: $3.01 million
• Optionable: No Data
• Beta: 1.22